ÂÜÀòÂÒÂ×

Erik Gutierrez has a diverse work experience spanning over several companies and roles. Erik'smost recent position was at Biosplice Therapeutics, where they served as the Executive Director of Business Development starting in September 2021. Prior to that, they were the Senior Director of Business Development at Esperion - The Lipid Management Company from August 2019 to September 2021.

Before joining Esperion, Erik worked at Alexion Pharmaceuticals, Inc. as the Associate Director of Business Development, Strategic Evaluation from April 2018 to August 2019. Erik also has experience in Biogen, serving in various roles such as New Product Commercialization from February 2017 to April 2018, Strategic Insights & Analytics in Global Commercial Strategy from October 2016 to February 2017, and Fellow in Corporate Development & Strategy from December 2014 to October 2016.

Erik's earlier work experience includes being a Predoctoral Research Fellow at Johns Hopkins University - National Institutes of Health from June 2009 to December 2014, and a Scientist at Novartis Institutes for BioMedical Research from May 2004 to June 2009, specifically in the Centers for Proteomic Chemistry.

Overall, Erik Gutierrez has amassed a strong background in business development, strategic evaluation, commercial strategy, and research, working in both pharmaceutical and biomedical research sectors.

Erik Gutierrez holds a Bachelor of Science (BS) degree in Biochemistry from Boston College. Erik also has a Doctor of Philosophy (PhD) degree in Cell, Molecular, Developmental Biology, and Biophysics from The Johns Hopkins University.

In addition to their formal education, Erik has obtained several certifications. In February 2016, they obtained a certification in "Valuation: Alternative Methods" from Coursera Course Certificates. Erik also holds certifications in "Principles of Valuation: Risk and Return" and "Principles of Valuation: Time Value of Money" from Coursera Verified Certificates, which they obtained in December 2015 and October 2015, respectively.